Tissue localization of photosensitizers and the mechanism of photodynamic tissue destruction.

This paper outlines our present knowledge of photosensitizer tissue distribution, derived from preclinical animal studies, and relates it to the observed biological response to photodynamic therapy (PDT). Emphasis is placed on porphyrins (haematoporphyrin derivative (HpD), Photofrin II) and phthalocyanines (aluminum phthalocyanine sulphonate AlPcS). In mice, both groups of sensitizers show multiphasic plasma clearance kinetics with an initial rapid decline followed by further slow reduction. Residual amounts of Photofrin II are detectable 75 days after injection. Drug elimination occurs through urine and faeces, but faecal elimination predominates for Photofrin II. Circulating sensitizer greatly influences the mouse ear-swelling response, but not the foot response. Tumours and normal skin can be destroyed by vascular damage, if illumination occurs at times of maximal plasma sensitizer concentration, with no detectable sensitizer accumulation in tumour cells. Organ retention for both photosensitizer groups is similar and persistent. Organs rich in reticuloendothelial elements (liver, kidney, spleen) accumulate and retain the highest levels, skin and muscle the lowest, while normal brain tissue excludes sensitizer. The adrenal and pancreatic glands, as well as urinary bladder, also retain high amounts of Photofrin II. Tumour/skin ratios of 1 to 3:1 and 2 to 7:1 have been reported for porphyrins and sulphonated phthalocyanines respectively. Tissue destruction upon light exposure is not always correlated with photosensitizer levels, as is exemplified by liver and pancreas. Stromal sensitizer localization usually predominates in tumour and normal tissue, and often determines tumour response. Certain compounds, such as monosulphonated tetraphenylporphyrin and AlPcS, may favour parenchymal localization. The formed blood elements remain free of photosensitizer, while mast cells and macrophages accumulate especially large amounts and, upon illumination, release an array of vasoactive inflammatory and immune mediators.

[1]  M. Berns,et al.  Study of the in vivo and in vitro photosensitizing capabilities of uroporphyrin I compared to photofrin II , 1986, Lasers in surgery and medicine.

[2]  K. Brackett,et al.  Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma , 1988, Journal of surgical oncology.

[3]  E. Reddi,et al.  Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo. , 1984, Cancer letters.

[4]  T. Mang,et al.  PHOTODYNAMIC THERAPY IN THE TREATMENT OF PANCREATIC CARCINOMA: DIHEMATOPORPHYRIN ETHER UPTAKE and PHOTOBLEACHING KINETICS , 1987, Photochemistry and photobiology.

[5]  B W Henderson,et al.  Modification of photodynamic therapy-induced hypoxia by fluosol-DA (20%) and carbogen breathing in mice. , 1988, Cancer research.

[6]  C J Gomer,et al.  Molecular, cellular, and tissue responses following photodynamic therapy , 1988, Lasers in surgery and medicine.

[7]  M W Berns,et al.  Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. , 1988, Journal of the National Cancer Institute.

[8]  J. Marshall,et al.  Tissue uptake, distribution, and potency of the photoactivatable dye chloroaluminum sulfonated phthalocyanine in mice bearing transplantable tumors. , 1988, Cancer research.

[9]  T. Dougherty,et al.  Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. , 1981, Cancer research.

[10]  R. Keck,et al.  Histological study of the effect of hematoporphyrin derivative photodynamic therapy on the rat jejunum. , 1986, Cancer research.

[11]  D. Kessel,et al.  Porphyrin-lipoprotein association as a factor in porphyrin localization. , 1986, Cancer letters.

[12]  W. Star,et al.  Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. , 1986, Cancer research.

[13]  H. Baden,et al.  The metabolic response to exfoliation. , 1962, The Journal of investigative dermatology.

[14]  R. Straight,et al.  Preliminary studies with implanted polyvinyl alcohol sponges as a model for studying the role of neointerstitial and neovascular compartments of tumors in the localization, retention and photodynamic effects of photosensitizers. , 1985, Advances in experimental medicine and biology.

[15]  B. Henderson,et al.  DRUG and LIGHT DOSE DEPENDENCE OF PHOTODYNAMIC THERAPY: A STUDY OF TUMOR and NORMAL TISSUE RESPONSE , 1987, Photochemistry and photobiology.

[16]  F. Kerdel,et al.  In vivo mediator release and degranulation of mast cells in hematoporphyrin derivative-induced phototoxicity in mice. , 1987, The Journal of investigative dermatology.

[17]  Michael T. Tseng,et al.  PHOTODYNAMIC THERAPY INDUCED ULTRASTRUCTURAL ALTERATIONS IN MICROVASCULATURE OF THE RAT CREMASTER MUSCLE , 1988, Photochemistry and photobiology.

[18]  C. Gomer,et al.  ACUTE SKIN RESPONSE IN ALBINO MICE FOLLOWING PORPHYRIN PHOTOSENSITIZATION UNDER OXIC AND ANOXIC CONDITIONS , 1984, Photochemistry and photobiology.

[19]  S. Britton,et al.  Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. , 1984, Cancer research.

[20]  J. H. Kinsey,et al.  Detection and localization of In situ carcinoma of the bladder with hematoporphyrin derivative. , 1982, Mayo Clinic proceedings.

[21]  A. Oseroff,et al.  Intramitochondrial dyes allow selective in vitro photolysis of carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Elmets,et al.  Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. , 1986, Cancer research.

[23]  B W Henderson,et al.  OXYGEN LIMITATION OF DIRECT TUMOR CELL KILL DURING PHOTODYNAMIC TREATMENT OF A MURINE TUMOR MODEL , 1989, Photochemistry and photobiology.

[24]  T. Mang,et al.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. , 1985, Cancer research.

[25]  D. Kessel,et al.  TUMOR LOCALIZATION AND PHOTOSENSITIZATION BY SULFONATED DERIVATIVES OF TETRAPHENYLPORPHINE , 1987, Photochemistry and photobiology.

[26]  T. Dougherty,et al.  CARBON‐14 LABELING AND BIOLOGICAL ACTIVITY OF THE TUMOR‐LOCALIZING DERIVATIVE OF HEMATOPORPHYRIN , 1988, Photochemistry and photobiology.

[27]  T J Dougherty,et al.  THE TIME COURSE OF CUTANEOUS PORPHYRIN PHOTOSENSITIZATION IN THE MURINE EAR , 1989, Photochemistry and photobiology.

[28]  T. Dougherty,et al.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. , 1979, Cancer research.

[29]  J Moan,et al.  Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. , 1985, Cancer Research.

[30]  T J Dougherty,et al.  DISTRIBUTION AND ELIMINATION OF PHOTOFRIN II IN MICE , 1989, Photochemistry and photobiology.